DRUG NAME MECHANISM OF ACTION INDICATION / ADVERSE EFFECT NURSING

CONTRAINDICATION RESPONSIBILITIES

GENERIC: Inhibits protein synthesis by binding directly to INDICATIONs: CNS: BEFORE:

AMIKACIN SULFATE the 30S ribosomal sub unit; bactericidal. The Uncomplicated UTI caused by Neuromuscular blockade Dx:
BRAND: primary mechanism of action of amikacin is the organism susceptible to less toxic EENT: a. Check for allergies.
AMIKIN same as that for all aminoglycosides. It binds to drugs. Active tuberculosis, with Ototoxicity b. Weigh patient and review
CLASS: bacterial 30S ribosomal subunits and interferes other antituberculotics. renal function studies.
AMINOGLYCOSIDE with mRNA binding and tRNA acceptor sites, Tx:
THERAPEUTIC interfering with bacterial growth. This leads to CONTRAINDICATION: a. Periodically assess dose.
ANTIDEPRESSANTS disruption of normal protein synthesis and Contraindicated in patients b. Evaluate patient’s
production of non-functional or toxic peptides. hypersensitive to drug or other hearing if he will be
PHARMACOLOGIC: Other actions have been postulated for drugs of aminogycosides. Use cautiously receiving drug for no
this class.Label, Amikacin, as well as the rest of in patients with impaired renal longer than 2 weeks.
DOSAGE: the aminoglycosides, are generally bacteriocidal function or neuromuscular Notify prescriber if
50 mg, 250 mg against gram-positive and gram-negative disorders, in neonates and infants patient has tinnitus,
bacteria. and in elderly patients. vertigo, or hearing loss.
ROUTE: c. Weigh patient and
IV, IM SOURCE: Amikacin. (n.d.). Go.drugbank.com. review renal function
https://go.drugbank.com/drugs/DB00479 studies.
EDx:
a. Educate client on drug
therapy to promote
compliance.
b. Insure the patient
receives the medication
as prescribed.

DURING:
Dx:
a. Monitor mood changes.
b. Monitor for adverse
effects
Tx:
a. Assist patient in taking
 the medication.
b. Evaluate patient’s
hearing if he will be
receiving drug for no
longer than 2 weeks.
Notify prescriber if
patient has tinnitus,
vertigo, or hearing loss.
c. Watch for signs and
symptoms of super
infection (especially
URT), such as continued
fever, chills, and
increased pulse rate.
EDx:
a. Instruct patient to
verbalize feelings and
concerns.

AFTER:
Dx:
a. Assess knowledge/teach
patient appropriate
use ,interventions to
reduce side effects, and
adverse symptoms to
report.
b. Monitor for effectiveness
as exhibited by a
decrease in symptoms
c. Monitor for side effects.
Tx:
a. Provide safety measures
(e.g. adequate lighting,
raised side rails, etc.) to
 prevent injuries.
b. Provide comfort
measures (e.g. voiding
before dosing, taking
food with drug, etc.) to
help patient tolerate drug
effects.
EDx:
a. Monitor patient
compliance to drug
therapy.
b. Monitor patient for 2-4
weeks to ascertain onset
of full therapeutic effect.
c. Instruct patient to
verbalize feelings and
concerns.